Liraglutide, a proposed diabetes drug, could increase the risk for heart problems and thyroid tumors, according to some studies conducted by drug maker Novo Nordisk. The FDA will determine exactly risks associated with liraglutide. Current data were insufficient to determine whether potential heart or thyroid risks exist.
Hopefully, this issue with liraglutide gets sorted out before liraglutide goes on to the market. I’m not prejudging the results. It would seem the process is working as it should: Novo Nordisk tells the FDA there is a concern and the FDA and the drug company work to sort of the concern.